This risk assessment contains updated advice to travellers and health professionals and the latest information on the epidemiological situation of yellow fever in Brazil.
This risk assessment is triggered by the increase in the number of yellow fever cases among EU travellers with exposure in South America since August 2016 and assesses the risk of contracting yellow fever for travellers to South America.
Due to its propensity to cause outbreaks and its antifungal resistance, C. auris poses a risk for patients in healthcare facilities in Europe. Difficulties with laboratory identification, combined with a lack of awareness of this new Candida species, might result in unnoticed outbreaks. There is a clear need to raise awareness in European healthcare facilities in order adapt laboratory testing strategies and implement enhanced control measures to prevent further hospital outbreaks.
In view of new evidence, ECDC has updated its rapid risk assessment on the potential risk of invasive cardiovascular infection by M. chimaera associated with the use of heater-cooler units.
This risk assessment evaluates the risk of yellow fever infection, which has seen outbreaks in Angola, Democratic Republic of Congo and Uganda, being introduced into Europe, and sets out a range of options for response.
This report summarises the results of a joint ECDC–European Commission mission team sent to review the epidemiological situation of yellow fever in Angola, following an outbreak in 2015-16.